Charles F. Wagner Jr. - 06 Jan 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: EVP, CO & FO
Issuer ticker: VRTX
Reported as of: 06 Jan 2026
Net transaction value: -$2,589,082
SEC form: 4
Accepted by SEC: 08 Jan 2026, 16:04:39 UTC
Prior SEC filing: 05 Dec 2025
Next SEC filing: 26 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Christiana Stevenson, Attorney-in-Fact

Key filing fact

Charles F. Wagner Jr. filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 08 Jan 2026.

Key facts

This page summarizes Charles F. Wagner Jr.'s Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jan 2026, 16:04.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: -$2,589,082.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001223348 Primary reporting owner

WAGNER CHARLES F JR

Relationship: EVP, CO & FO
Address: C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Signature date: 08 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRTX transaction

Common Stock

Options Exercise

Transaction value: $1,805,170
Shares: +9,532
Change %: +25%
Price: $189.38
Shares after: 47,257
Date: 06 Jan 2026
Ownership: Direct

VRTX transaction

Common Stock

Sale

Transaction value: $4,394,252
Shares: -9,532
Change %: -20%
Price: $461.00
Shares after: 37,725
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRTX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -9,532
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 06 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,532
Exercise price: $189.38
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 5/09/2025.

Footnote F2

Fully vested.